Clinical Trials Details

A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)(ASTRIDE)(Hengenix HLX10-005-SCLC301-E)(NCT05468489)

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.

Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:

  • Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
  • Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

Learn More

Principal Investigator(s)

Salvatore Del Prete, MD


Ed Hatton, RN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.